Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 817

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 817
---
2023-09is effective for annual periods beginning after December 15, 2024 and can be applied prospectively or retrospectively. The Company has not adopted ASU 2023-09yet and does not expect the adoption of this ASU to have a material impact on the Company’s consolidated financial statements. 3. Reverse Merger On December 16, 2022, the Company completed the Merger with Private Kineta (see Note 1). The transaction was determined to be a reverse merger primarily based on the fact that, immediately following the Merger: (i) Private Kineta’s shareholders own a majority (80%) of the common stock of the Company, (ii) Private Kineta designated a majority of the members of the initial board of directors of the combined organization and (iii) Private Kineta’s senior management hold all key positions in the senior management of the combined organization. At the closing of the Merger, all shares of Private Kineta common stock were exchanged for an aggregate of 6,115,000 shares the Company’s common stock. The reverse merger was accounted for as an acquisition of assets as substantially all of the fair value was concentrated in cash and IPR&D. In connection with the Merger, the authorized shares of common stock of the Company are 125,000,000 with par value of $0.001.

| Number of shares owned by Yumanity shareholders (1)                          |     | (in thousands) |  1,553 |
|:-----------------------------------------------------------------------------|:----|:---------------|-------:|
| Multiplied by fair value per share of Yumanity common stock (2)              |     | $              |  13.23 |
| Fair value of shares of combined organization owned by Yumanity shareholders |     |                | 20,551 |
| Transaction costs (3)                                                        |     |                |  5,641 |
| Total purchase price                                                         |     | $              | 26,192 |

| (1) | The number of shares represents 1,551,000 shares of Yumanity common stock outstanding as of December 16, 2022 and 2,000 shares of restricted stock units and reflects the impact of the Reverse Stock Split. |

| (2) | Based on the closing price of Yumanity common stock on the Nasdaq Capital Market on December 16, 2022, the closing date of the Merger and after giving effect to the Reverse Stock Split. |

|